October 04, 2022
To the clinic!
… in patients. Choi’s mouse studies pinpointed aberrant development and hyperactivity in the S1DZ area of the mouse … for having co-founded Seaside Therapeutics to spur development and testing of a promising treatment his lab … started a new company, Allos Pharma Inc., to continue development and testing. In parallel with her in-house …

